Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (12) : 1078-1081     DOI: 10.3971/j.issn.1000-8578.2021.21.0756
|
Expression and Clinical Significance of Serum PTX3 in Hepatocellular Carcinoma
PANG Kangqing, MA Hongde, YANG Rulei, PANG Guohong
Department of Infectious Diseases, Pingdingshan First People’s Hospital, Pingdingshan 467000, China
Download: PDF(3321 KB)   ( 54 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To investigate the expression and clinical significance of serum PTX3 in HCC patients. Methods We selected 78 HCC patients as the liver cancer group, and 78 cases of healthy subjects as the healthy control group. The PTX3 levels were detected and compared between the two groups. The differences of PTX3 levels in patients with different pathological characteristics were analyzed. ROC curve was used to analyze the auxiliary diagnostic value of serum PTX3 in HCC. Results PTX3 level in HCC patients was higher than that in healthy control group (P<0.05). PTX3 level in stage Ⅰ group was higher than those in the stage Ⅱ group and Ⅲ group (P<0.05). PTX3 level in patients with tumor ≥5cm was significantly lower than that with tumor diameter <5cm (P<0.05). In addition, PTX3 level in patients with HBV infection was significantly higher than that without HBV infection (P<0.05). The AUC was 0.938. Conclusion The serum PTX3 level is significantly increased in patients with HCC. It has auxiliary diagnostic value for HCC.
Keywords Pentrin-3      Hepatocellular carcinoma      Clinical diagnosis value     
ZTFLH:  R735.7  
Issue Date: 13 December 2021
 Cite this article:   
PANG Kangqing,MA Hongde,YANG Rulei, et al. Expression and Clinical Significance of Serum PTX3 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1078-1081.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0756
http://www.zlfzyj.com/EN/Y2021/V48/I12/1078
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
PANG Kangqing
MA Hongde
YANG Rulei
PANG Guohong
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide
for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,
71(3): 209-249.
[2] Parikh ND, Mehta AS, Singal AG, et al. Biomarkers for the Early
Detection of Hepatocellular Carcinoma[J]. Cancer Epidemiol
Biomarkers Prev, 2020, 29(12): 2495-2503.
[3] 曹丽荣. 肿瘤标志物联合甲胎蛋白检测方法在原发性肝癌患
者中的诊断研究[J]. 中国药物与临床, 2017, 17(6): 909-911.
[Chao LR. Study on the diagnosis of primary liver cancer patients
with tumor markers combined with alpha-fetoprotein detection[J].
Zhongguo Yao Wu Yu Lin Chuang, 2017, 17(6): 909-911.]
[4] 陈利君, 陈静琦, 曾波航. 肝癌组织中CD68+肿瘤相关巨噬细胞
数量与Ki-67蛋白表达及原发性肝癌预后的关系[J]. 肿瘤防治
研究, 2016, 43(9): 774-778. [Chen LJ, Chen JQ, Zeng BH, et al.
Correlation of CD68+ Tumor-associated Macrophages Number
with Ki-67 Expression and Prognosis of Patients with Primary
Hepatocellular Carcinoma [J]. Zhong Liu Fang Zhi Yan Jiu, 2016,
43(9): 774-778.]
[5] Inforzato A, Doni A, Barajon I, et al. PTX3 as a paradigm for the
interaction of pentraxins with the complement system[J]. Semin
Immunol, 2013, 25(1): 79-85.
[6] Rubino M, Kunderfranco P, Basso G, et al. Epigenetic regulation
of the extrinsic oncosuppressor PTX3 gene in inflammation and
cancer[J]. Oncoimmunology, 2017, 6(7): e1333215.
[7] Doni A, Stravalaci M, Inforzato A, et al. The Long Pentraxin
PTX3 as a Link Between Innate Immunity, Tissue Remodeling,
and Cancer[J]. Front Immunol, 2019, 10: 712.
[8] Daigo K, Inforzato A, Barajon I, et al. Pentraxins in the activation
and regulation of innate immunity[J]. Immunol Rev, 2016, 274(1):
202-217.
[9] Liu B, Zhao Y, Guo L. Increased serum pentraxin-3 level predicts
poor prognosis in patients with colorectal cancer after curative
surgery, a cohort study[J]. Medicine (Baltimore), 2018, 97(40):
e11780.
[10] Infante M, Allavena P, Garlanda C, et al. Prognostic and
diagnostic potential of local and circulating levels of pentraxin 3
in lung cancer patients[J]. Int J Cancer, 2016, 138(4): 983-991.
[11] Choi B, Lee EJ, Park YS, et al. Pentraxin-3 Silencing Suppresses
Gastric Cancer-related Inflammation by Inhibiting Chemotactic
Migration of Macrophages[J]. Anticancer Res, 2015, 35(5):
2663-2668.
[12] Song T, Wang C, Guo C, et al. Pentraxin 3 overexpr‍ession
accelerated tumor metastasis and indicated poor prognosis in
hepatocellular carcinoma via driving epithelial-mesenchymal
transition[J]. J Cancer, 2018, 9(15): 2650-2658.
[13] 中华人民共和国卫生和计划生育委员会医政医管局. 原发
性肝癌诊疗规范(2017年版)[J]. 中华消化外科杂志, 2017,
16(7): 635-647. [Bureau of Medical Administration, Health and
Family Planning Commission of the People’s Republic of China.
Standardization of diagnosis and treatment for hepatocellular
carcinoma(2017 edition)[J]. Zhonghua Xiao Hua Wai Ke Za Zhi,
2017, 16(7): 635-647.]
[14] 叶冬雪, 刘芬, 杨茜, 等. Mina53与CBX8在肝细胞肝癌中的表
达及其与临床病理特征和预后的关系[J]. 肿瘤防治研究, 2020,
47(6): 451-456. [Ye DX, Liu F, Yang Q, et al. Expression of Mina
53 and CBX8 in Hepatocellular Carcinoma and Their corelation
with Clinicopathological Features and Prognosis[J]. Zhong Liu
Fang Zhi Yan Jiu, 2020, 47(6): 451-456.]
[15] 赵荣荣, 邓永东, 袁宏. 236例原发性肝癌患者流行病学及临床
特点分析[J]. 临床肝胆病杂志, 2016, 32(8): 1538-1542. [Zhao
RR, Deng YD, Yuan H. Epidemiological and clinical features of
primary liver cancer: an analysis of 236 patients[J]. Lin Chuang
Gan Dan Bing Za Zhi, 2016, 32(8): 1538-1542.]
[16] 程书平, 李明, 谭诗云. 血清AFP、PIVKA-Ⅱ、GGT、GGT/
ALT检测对早期原发性肝癌的诊断价值[J]. 山东医药, 2021,
26(1): 61-65. [Cheng SP, Li M, Tan SY. The diagnostic value of
serum AFP, PIVKA-Ⅱ, GGT, GGT/ALT for early primary liver
cancer[J]. Shandong Yi Yao, 2021, 26(1): 61-65.]
[17] 杨文聪, 魏统双. 血清miR-122-5p水平联合MSCT对肝癌的诊
断价值[J]. 中国CT和MRI杂志, 2021, 19(4): 86-89. [Yang WC,
Wei TS. Diagnostic value of serum miR-122-5p level combined
with MSCT for liver cancer[J]. Zhongguo CT He MRI Za Zhi,
2021, 19(4): 86-89.]
[18] 刘毓键, 马明洋. 血清标志物在肝细胞肝癌早期诊断中的研究
进展及应用前景[J]. 医学综述, 2020, 26(7): 1325-1330, 1336.
[Liu YJ, Ma MY. Research progress and application prospect of
serum markers in early detection of hepatocellular carcinoma[J].
Yi Xue Zong Shu, 2020, 26(7): 1325-1330, 1336.]
[19] 彭婉君, 赵彬彬, 武婧, 等. 可溶性识别分子PTX3的研究进
展[J]. 中国比较医学杂志, 2020, 30(1): 115-121. [Peng WJ,
Zhao BB, Wu J, et al. Research progress on soluble recognition
molecule PTX3[J]. Zhongguo Bi Jiao Yi Xue Za Zhi, 2020, 30(1):
115-121.]
[20] Deng H, Fan X, Wang X, et al. Serum pentraxin 3 as a biomarker
of hepatocellular carcinoma in chronic hepatitis B virus
infection[J]. Sci Rep, 2020, 10(1): 20276.
[21] 代伟伟, 刘正新, 徐宝宏. 肝硬化和肝癌患者血清CA125、
CA199、AFP和CEA水平变化[J]. 实用肝脏病杂志, 2017,
20(1): 81-84. [Dai WW, Liu ZX, Xu BH. Serum CA125, CA199,
AFP, CEA in patients with cirrhosis and primary liver cancer[J].
Shi Yong Gan Zang Bing Za Zhi, 2017, 20(1): 81-84.]
[22] Feder S, Haberl E M, Spirk M, et al. Pentraxin-3 is not related
to disease severity in cirrhosis and hepatocellular carcinoma
patients[J]. Clin Exp Med, 2020, 20(2): 289-297.
[23] Bonavita E, Gentile S, Rubino M, et al. PTX3 Is an Extrinsic
Oncosuppr e s sor Regul a t ing Compl ement -Dependent
Inflammation in Cancer[J]. Cell, 2015, 160(4): 700-714.

Related articles from Frontiers Journals
[1] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[2] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[3] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[4] ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
[5] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[6] XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
[7] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[8] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[9] CUI Honglei, ZHANG Xiaodan, GUO Danfeng, YAN Zhiping, GUO Wenzhi, ZHANG Shuijun. Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 438-443.
[10] ZHOU Yongjie, WANG Zhengfeng, YAN Jun, WANG Haiping, XU Wen, ZHOU Wence. Value of Preoperative Lactate Dehydrogenase-to-Albumin Ratio Combined with AFP in Evaluating Prognosis of Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 347-351.
[11] TAO Changcheng, ZHANG Kai, RONG Weiqi, WU Jianxiong. Research Progress of Early Recurrence and Cut-off Time of Hepatocellular Carcinoma after Radical Hepatectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 359-363.
[12] ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong. Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 213-218.
[13] CHEN Long, LIU Yujie, TIAN Suqing, WANG Cuiying, HE Donglei. Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 53-57.
[14] SONG Yanzhou, ZHANG Kun, CHEN Qijun, WEI Wenping, ZHAO Xin, LI Zhiwei, LI Wei. Experiment on Inhibiting NEK7 to Promote Apoptosis of Hepatocellular Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 929-933.
[15] XU Gang, BU Shanshan, WANG Xiushen, GE Hong. Correlation Between cyclin G1 Expression and Efficacy of Radiotherapy on Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 958-962.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed